WO1998045429A3 - Polypeptides involved in the staurosporine induced apoptotic pathway - Google Patents

Polypeptides involved in the staurosporine induced apoptotic pathway Download PDF

Info

Publication number
WO1998045429A3
WO1998045429A3 PCT/EP1998/002157 EP9802157W WO9845429A3 WO 1998045429 A3 WO1998045429 A3 WO 1998045429A3 EP 9802157 W EP9802157 W EP 9802157W WO 9845429 A3 WO9845429 A3 WO 9845429A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
apoptotic pathway
staurosporine
polypeptides involved
induced apoptotic
Prior art date
Application number
PCT/EP1998/002157
Other languages
French (fr)
Other versions
WO1998045429A2 (en
Inventor
Dominik Imfeld
Peter Fuerst
Patrick Schindler
Walter Maerki
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Dominik Imfeld
Peter Fuerst
Patrick Schindler
Walter Maerki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Dominik Imfeld, Peter Fuerst, Patrick Schindler, Walter Maerki filed Critical Novartis Ag
Priority to AU75248/98A priority Critical patent/AU7524898A/en
Publication of WO1998045429A2 publication Critical patent/WO1998045429A2/en
Publication of WO1998045429A3 publication Critical patent/WO1998045429A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to polypeptides involved in the apoptotic pathway, to a process of isolating said polypeptides, to polypeptides obtainable by said process, to the use of said polypeptides as a marker or surrogate marker of a cellular condition achievable by application of staurosporine to a cell, as a diagnostic marker or surrogate marker for a disease responsive to an induction or inhibition of a cellular condition achievable by application of staurosporine to a cell and to pharmaceutical compositions comprising said polypeptides.
PCT/EP1998/002157 1997-04-10 1998-04-14 Polypeptides involved in the staurosporine induced apoptotic pathway WO1998045429A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75248/98A AU7524898A (en) 1997-04-10 1998-04-14 Polypeptides involved in the staurosporine induced apoptotic pathway

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9707307.6A GB9707307D0 (en) 1997-04-10 1997-04-10 Polypeptide markers
GB9707307.6 1997-04-10

Publications (2)

Publication Number Publication Date
WO1998045429A2 WO1998045429A2 (en) 1998-10-15
WO1998045429A3 true WO1998045429A3 (en) 1999-04-15

Family

ID=10810608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/002157 WO1998045429A2 (en) 1997-04-10 1998-04-14 Polypeptides involved in the staurosporine induced apoptotic pathway

Country Status (3)

Country Link
AU (1) AU7524898A (en)
GB (1) GB9707307D0 (en)
WO (1) WO1998045429A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101346527B1 (en) 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 Amine compound and use thereof for medical purposes
ES2491224T3 (en) 2006-04-28 2014-09-05 Mitsubishi Tanabe Pharma Corporation 2-aminobutanol compound and its use for medical purposes
US10898609B2 (en) 2015-07-15 2021-01-26 University Of Florida Research Foundation, Inc. Tissue decellularization methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013802A1 (en) * 1992-12-10 1994-06-23 Cytomed, Inc. D4 gene and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013802A1 (en) * 1992-12-10 1994-06-23 Cytomed, Inc. D4 gene and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANLEY DE ET AL: "Defective Rho GTPase regulation by IL-1 beta-converting enzyme-mediated cleavage of D4 GDP dissociation inhibitor.", J IMMUNOL, JUL 15 1996, 157 (2) P500-3, UNITED STATES, XP002084619 *
JARVIS, W. DAVID ET AL: "Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C", CANCER RES. (1994), 54(7), 1707-14 CODEN: CNREA8;ISSN: 0008-5472, XP002084622 *
NA S ET AL: "D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis.", J BIOL CHEM, MAY 10 1996, 271 (19) P11209-13, UNITED STATES, XP002084618 *
WANG, SHUJIE ET AL: "Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-.beta.-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2", MOL. PHARMACOL. (1997), 52(6), 1000-1009 CODEN: MOPMA3;ISSN: 0026-895X, XP002084621 *
ZHANG, HAICHAO ET AL: "Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases", PROSTATE (N. Y.) (1996), 29(2), 69-76 CODEN: PRSTDS;ISSN: 0270-4137, XP002084620 *

Also Published As

Publication number Publication date
AU7524898A (en) 1998-10-30
GB9707307D0 (en) 1997-05-28
WO1998045429A2 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
TR200200785T2 (en) 8-Phenyl-6,9-dihydro- [1,2,4] triazolo [3,4-i] purin-5-one derivatives
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
HUP0003386A3 (en) Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases
WO2001038547A3 (en) Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
ZA975947B (en) Aqueous-based pharmaceutical composition.
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
BR9805993B1 (en) aerosol pharmaceutical composition.
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
IL135920A0 (en) 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
NO20016038D0 (en) Benzene derivatives, processes for their preparation and pharmaceutical compositions containing the same
AU7912100A (en) Pharmaceutical composition comprising an antigen
IL131415A (en) Anti-inflammatory compounds, processes for their preparation and pharmaceutical compositions comprising them
AU6799000A (en) Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or pro-ms immune response
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
KR100547921B1 (en) Sulfonamide-substituted chromamann, methods for the preparation thereof and pharmaceutical compositions comprising the same
ZA987536B (en) Stanol comprising compositions.
HUP0303653A3 (en) Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
HUP0000851A3 (en) Novel pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
IL139480A0 (en) Epothilone derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
AU9534398A (en) Novel pharmaceutical composition
IL146104A0 (en) Substituted bicyclic heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing the same
IL137365A0 (en) Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0003398A2 (en) Novel triptolide derivatives and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998542414

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA